Diligence memo · auto-generated · as of July 2, 2026
Dna Seq 2, Inc.
Dna Seq 2, Inc. looks under-valued against its niche peers and is at-risk on financing cadence.
Businessfiled
Dna Seq 2, Inc. operates in Pharmaceuticals, based in VISTA.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Dna Seq 2, Inc. has raised $1.2M in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Seed (a $1.0M–$4.0M round).
Largest single filing: $1.2M on 2024-04-10.
Most recent recorded round closed around 2024-04-10.
Valuation (modeled)modeled
Provath models Dna Seq 2, Inc. at approximately $6.3M (range $889K–$18M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Under-valued. Modeled value is 0.65× the median modeled value of Seed Pharmaceuticals companies in 2022–2024 (50 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Last raise 2.2 yr ago; this sector typically re-raises about every 13 months.
Past due for a raise versus sector cadence — watch for distress or a bridge.
Comparablesmixed
Capital scale ranks ahead of 21% of Pharmaceuticals peers (1613 compared).
Modeled value ranks above 11% of those peers.
Closest niche peers: Celeris Therapeutics, Inc., Oligomerix, Inc., 2A Biosciences, Inc., Myosin Therapeutics Inc., Eluciderm Inc..
Peoplefiled
6 named people on file across officers, directors and signatories.
Risks & flagsmixed
Overdue for a raise versus sector norm — distress or bridge risk.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.